Vaxcyte: Buy Rated on Superior VAX-31 Coverage, Robust Phase 3 OPUS Program, and Strong Cash Runway Through 2028

Thomas Shrader, an analyst from BTIG, maintained the Buy rating on Vaxcyte. The associated price target was raised to $89.00.

Thomas Shrader has given his Buy rating due to a combination of factors that collectively point to a strong competitive position for Vaxcyte. He highlights that VAX-31’s substantially wider serotype coverage versus current pneumococcal vaccines, including marketed products and Pfizer’s next-generation candidate, is likely to translate into superior clinical and commercial performance in both adult and pediatric populations.

He also emphasizes the robust and well-designed Phase 3 OPUS program, which directly compares VAX-31 with leading competitors and explores high-value segments such as previously vaccinated adults, potentially unlocking a sizeable catch-up market if boosting data are compelling. In addition, Shrader notes the company’s solid balance sheet, with cash resources expected to fund operations through at least 2028, providing sufficient runway to reach multiple pivotal data readouts and value inflection points without near-term financing pressure.

In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $133.00 price target.